Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First in Human Adaptive Study to Investigate the Kinetic Properties of the Novel PET Radioligand [11C]CHDI-00491009 and Its Suitability for Quantification of Aggregated Mutant Huntingtin in the Brains of People With Huntington's Disease

NCT06634628 is registered in ClinicalTrials.gov with CHDI Foundation, Inc. as lead sponsor.

NCT NCT06634628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06634628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First in Human Adaptive Study to Investigate the Kinetic Properties of the Novel PET Radioligand [11C]CHDI-00491009 and Its Suitability for Quantification of Aggregated Mutant Huntingtin in the Brains of People With Huntington's Disease
Lead sponsor
CHDI Foundation, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 24, 2026
Completion date
March 31, 2028
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hd, huntington disease, huntington's, huntington's disease, imaging, mhtt, pet tracer, positron emission tomography, radioligand